Skip to main content

Table 1 Clinical characteristics of 247 NF cases and antimicrobial resistance of CA- and HA-MRSA isolates

From: Retrospective study of necrotizing fasciitis and characterization of its associated Methicillin-resistant Staphylococcus aureusin Taiwan

Characteristic

Non-S. aureus

(n = 156)

MSSA

(n = 42)

CA-MRSA

(n = 25)

HA-MRSA

(n = 24)

p-value

Age (mean, yr)§

(years)

59.1 ± 13.0

56.0 ± 17.9

53.8 ± 14.3

57.4 ± 15.3

0.262

Male (n, %)

107 (68.6)

27 (64.3)

13 (52)

17 (70.8)

0.399

Comorbidities (n, %)†

1.8 (1.2)

1.9 (1.5)

1.4 (1.1)

2.9 (1.5)

<0.001***

Hospitalization (mean, day)§

17.2 ± 10.6

15 ± 8.6

13.2 ± 8.3

20.3 ± 8.1

0.052

Underlying chronic disease

     

Diabetes mellitus (n, %)

95 (60.9)

25 (59.5)

15 (60.0)

20 (83.3)

0.183

Hypertension (n, %)

59 (37.8)

17 (40.5)

7 (28.0)

11 (45.8)

0.616

Chronic hepatic disease (n, %)

19 (12.2)

8 (19)

4 (16)

5 (20.8)

0.451

Malignancy (n, %)

6 (3.8)

2 (4.8)

0 (0)

0 (0)

0.765

Obesity (n, %)

17 (10.9)

3 (7.1)

0 (0)

1 (4.2)

0.300

Pulmonary disease (n, %)

11 (7.1)

3 (7.1)

0 (0)

2 (8.3)

0.600

Chronic azotemia (n, %)

26 (16.7)

6 (14.3)

2 (8)

10 (41.7)

0.019*

Operative procedure (mean, n)

2.1 ± 1.1

1.9 ± 0.6

2.1 ± 0.9

2.4 ± 1.5

0.237

Reconstructive surgery (n, %)

15 (9.6)

2 (4.8)

8 (32)

7 (29.2)

<0.001***

Amputation (n, %)

18 (11.5)

2 (4.8)

2 (8)

7 (29.2)

0.037*

Mortality (n, %)

5 (3.2)

0 (0)

0 (0)

1 (4.2)

0.542

Site of infection

     

Upper extremity (n, %)

18 (11.5)

8 (19)

4 (16)

1 (4.2)

0.315

Lower extremity (n, %)

103 (66)

25 (59.5)

17 (68)

20 (83.3)

0.005**

Head and neck (n, %)

1 (0.6)

4 (9.5)

2 (8)

1 (4.2)

0.014*

Trunk (n, %)

34 (21.8)

5 (11.9)

2 (8)

2 (8.3)

0.118

Body temperature (°C) (mean)§

36.9 ± 0.8

36.9 ± 0.5

36.8 ± 0.5

37.1 ± 0.7

0.624

Shock (n, %)

4 (2.6)

0 (0)

2 (8)

1 (4.2)

0.170

Leukocyte count (mean cells/mm3)§

13.9 ± 7.4

14.1 ± 5.1

12.9 ± 5.5

15.1 ± 7.7

0.752

Platelet count (mean, per mm3)

248.3 ± 107.9

263.2 ± 96.9

290.5 ± 120.2

293.9 ± 99.5

0.101

C-reactive protein (mean, mg/dl)‡

15.8 ± 13.2

12.2 ± 11.8

10.4 ± 10.6

25.5 ± 14.8

0.005**

Antimicrobials resistance

  

CA-MRSA

HA-MRSA

 

Clindamycin (n, %)

  

23 (92.0)

23 (95.8)

0.576

Erythromycin (n, %)

  

23 (92.0)

23 (95.8)

0.576

Fucidic acid (n, %)

  

3 (12.0)

3 (12.5)

0.957

Trimethoprim-sulfamethoxazole (n, %)

  

1 (4.0)

11 (45.8)

<0.001***

  1. § Data represents as mean ± standard deviation or number of cases (prevalence, %).
  2. † Post hot comparison using Tukey mothod: Non-S. aureus < HA-MRSA, p = 0.001; MSSA < HA-MRSA, p = 0.02; CA-MRSA < HA-MRSA, p < 0.001.
  3. ‡ Post hot comparison using Tukey mothod: Non-S. aureus < HA-MRSA, p = 0.045; MSSA < HA-MRSA, p = 0.008; CA-MRSA < HA-MRSA, p = 0.007.
  4. * indicates significant differences among four groups (p < 0.05); ** and *** indicates highly significant among four groups with p < 0.01 and p < 0.001 respectively.
Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us